C Graux
Overview
Explore the profile of C Graux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janssen J, Lowenberg B, Manz M, Biemond B, Westerweel P, Klein S, et al.
Leukemia
. 2022 Jul;
36(9):2189-2195.
PMID: 35869267
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would...
2.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Aug;
34(10):2820.
PMID: 32733013
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
3.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Feb;
34(7):1751-1759.
PMID: 32020044
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome....
4.
Garcia-Manero G, Sekeres M, Egyed M, Breccia M, Graux C, Cavenagh J, et al.
Leukemia
. 2017 May;
31(12):2799-2806.
PMID: 28546581
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is <2 years, novel...
5.
Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, et al.
Acta Clin Belg
. 2014 Dec;
70(1):34-43.
PMID: 25444072
Objectives: We evaluated azacitidine (Vidaza(®)) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose,...
6.
Cornelissen J, Versluis J, Passweg J, van Putten W, Manz M, Maertens J, et al.
Leukemia
. 2014 Nov;
29(5):1041-50.
PMID: 25428261
The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher...
7.
Meers S, Breems D, Bries G, Delforge M, Graux C, Ravoet C, et al.
Acta Clin Belg
. 2014 Jan;
68(4):253-62.
PMID: 24455794
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characterized by ineffective haematopoiesis and an increased risk for leukemic transformation. In recent years several new therapeutics have emerged that...
8.
Vanhaudenarde V, Duck L, Mazzeo F, Graux C, Jamar F, Coche E, et al.
Acta Clin Belg
. 2013 Aug;
68(2):120-3.
PMID: 23967721
Haemangiopericytoma is a rare tumor of vascular origin. We report the case of patient with severe refractory anaemia due to peripheral destruction of red blood cells by spleen metastases. Anaemia...
9.
Caers J, Bonnet C, Graux C, De Prijck B, Beguin Y
Rev Med Suisse
. 2011 Oct;
7(306):1634, 1636-8, 1640-3.
PMID: 21972730
Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and...
10.
Put N, Meeus P, Chatelain B, Rack K, Boeckx N, Nollet F, et al.
Leukemia
. 2009 Mar;
23(6):1201-4.
PMID: 19295547
No abstract available.